• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Euro Surveill. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December

Giuseppe

Emeritus
[Source: Eurosurveillance, full text: (LINK). Abstract, edited.]

Eurosurveillance, Volume 17, Issue 12, 22 March 2012

Rapid communications


Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012


S Jim?nez-Jorge ()<SUP>1</SUP><SUP>,2</SUP>, S de Mateo<SUP>1</SUP><SUP>,2</SUP>, F Pozo<SUP>3</SUP>, I Casas<SUP>3</SUP>, M Garc?a Cenoz<SUP>2</SUP><SUP>,4</SUP>, J Castilla<SUP>2</SUP><SUP>,4</SUP>, V Gallardo<SUP>5</SUP>, E P?rez<SUP>5</SUP>, T Vega<SUP>6</SUP>, C Rodriguez<SUP>6</SUP>, C Quinones<SUP>7</SUP>, E Mart?nez<SUP>7</SUP>, J Gim?nez<SUP>8</SUP>, J M Vanrell<SUP>8</SUP>, D Castrillejo<SUP>9</SUP>, M C Serrano<SUP>10</SUP>, J M Ramos<SUP>10</SUP>, A Larrauri<SUP>1</SUP><SUP>,2</SUP>
  1. National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain
  2. Ciber Epidemiolog?a y Salud P?blica (CIBERESP), Ministry of Science and Innovation, Institute of Health Carlos III, Madrid, Spain
  3. National Centre for Microbiology, World Health Organization National Influenza Centre, Institute of Health Carlos III, Madrid, Spain
  4. Instituto de Salud P?blica de Navarra, Navarra, Spain
  5. Servicio de Epidemiolog?a y Salud Laboral. Secretar?a General de Salud P?blica y Participaci?n. Consejer?a de Salud de Andaluc?a, Seville, Spain
  6. Direcci?n General de Salud P?blica, Consejer?a de Sanidad de Castilla y Le?n, Valladolid, Spain
  7. Servicio de Epidemiolog?a, Subdirecci?n de Salud P?blica de La Rioja, La Rioja, Spain
  8. Servicio de Epidemiolog?a, Direcci?n General de Salut P?blica, Mallorca, Baleares, Spain
  9. Servicio de Epidemiolog?a, Direcci?n General de Sanidad y Consumo, Consejer?a de Bienestar Social y Sanidad, Ciudad Aut?noma de Melilla, Spain
  10. Direcci?n General de Salud P?blica, Servicio Extreme?o de Salud, Badajoz, Junta de Extremadura, Spain
<HR>
Citation style for this article: Jim?nez-Jorge S, de Mateo S, Pozo F, Casas I, Garc?a Cenoz M, Castilla J, Gallardo V, P?rez E, Vega T, Rodriguez C, Quinones C, Mart?nez E, Gim?nez J, Vanrell JM, Castrillejo D, Serrano MC, Ramos JM, Larrauri A. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. Euro Surveill. 2012;17(12):pii=20129. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20129
Date of submission: 06 March 2012
<HR>We present early estimates of influenza vaccine effectiveness (VE) in the population targeted for vaccination, during 25 December 2011 to 19 February 2012. The adjusted VE was 55% (95% CI: 3 to 79) against any type of influenza virus and 54% (95% CI: 1 to 79) against influenza A(H3N2) virus. This suggests a moderate protective effect of the vaccine in the targeted population in a late influenza epidemic with limited match between vaccine and circulating strains.
- ------
 
Back
Top Bottom